

Interferon Gamma Promoter is Hypermethylated in Blood DNA from Workers with Confirmed Diisocyanate Asthma

Ouyang B¹, Bernstein D², Lummus ZL², Ying J¹, Cartier A³, Gautrin, D³, Sastre J⁴, Boulet LP⁵, Quirce S⁴, Tarlo, SM⁶, Cruz, M⁷, Munoz, X⁷, Ho, SM¹

¹ University of Cincinnati College of Medicine, Department of Environmental Health Sciences, Cincinnati, Ohio; ² University of Cincinnati College of Medicine, Department of Internal Medicine, Cincinnati, Ohio; ³ Université de Montréal, Hôpital du Sacré-Cœur, Montreal, Québec, Canada;

⁴ Universidad Autónoma de Madrid, Allergy Department, Madrid, Spain; ⁵ Université Laval, Hôpital Laval, Sainte-Foy, Québec, Canada; ⁶ University of Toronto, Toronto, Ontario, Canada; ⁷ University at Autonomia of Barcelona, Hospital Vall d'Hebron, Barcelona, Spain.

Corresponding author: David I. Bernstein MD, Department of Medicine and Environmental Health Sciences, 3255 Eden Avenue, Suite 350, ML 563 Cincinnati, Ohio 45267-0563 bernstd@ucmail.uc.edu

Financial Disclosure: Nothing to disclose

Objectives: Diisocyanates (DIs) are leading causes of occupational asthma. Investigators are still unable to identify or define risk factors that determine susceptibility for development of DI-induced occupational asthma. Occupational chemical exposures could modify promoter regions regulating transcription of cytokine mediators or protective proteins and thereby influence expression of DA. To test this hypothesis, we performed a case control study of DI exposed workers with and without confirmed DA, investigating DNA methylation status of candidate gene promoter regions.

Methods: 131 subjects were studied including: 40 workers with DA (DA+) confirmed by a positive specific inhalation challenge (SIC); 41 exposed workers with lower respiratory symptoms and negative SICs (DA-); and 50 asymptomatic exposed workers (AWs). 10-11 subjects from each aforementioned group were current smokers and the rest never smokers. DNA was extracted from blood and bisulfite-converted for analysis of methylation status of gene promoters using methylation-specific-quantitative PCR.

Results: Promoter methylation status was measured for GSPM1, DUSP22, IFN- γ , and IL-4 genes. GSPM1 and DUSP22 showed no statistically difference in degree of promoter methylation among the three study groups. Non-smoking subjects in DA+ showed 4-7% less-methylation of IL-4 promoter compared to DA- and AW. Interestingly, smoking subjects showed about 14% increased IL-4 promoter methylation in DA+ compared to DA- and AW. The IFN- γ promoter, however, was found to be hypermethylated in DA+ (median 68.1% methylation) compared to DA- (median 37% methylation) and AW (median 31.7% methylation). The degree of methylation was statistically different among the subjects ($p=0.001$ in DA+ vs. DA-, $p=0.002$ in DA+ vs. AW). There was no difference in the degree of IFN- γ promoter methylation between DA- and AW ($p=0.70$). Univariate model had modest accuracy of IFN- γ methylation in identifying DA+ workers at 60% sensitivity and 81.3% specificity. Multivariate models through adjusting covariate predictors (exposure, smoking status, PC20 and gender) exhibited improved sensitivity (77.5%) and specificity (80%).

Conclusion: DA+ was highly associated with IFN- γ promoter hypermethylation. Methylation status of IFN- γ promoter, combining with multivariate model can differentiate DA from non-DA workers with relative high sensitivity and specificity.

Funding acknowledgement: This study was supported by NIOSH/CDC R01 OH008795 (DB), CA 112532 (SMH), ES015584 (SMH), ES018758 (SMH), ES018789 (SMH), ES015584 (SMH), ES018789 (SMH), ES015905 (SMH), ES019480 (SMH), and ES006096 (SMH).



ISOCYANATES & HEALTH

PAST, PRESENT  AND FUTURE

PROGRAM BOOK

WITH ABSTRACTS

APRIL 3-4, 2013 | BOLGER CONFERENCE CENTER | POTOMAC, MARYLAND

Government Agency Sponsors



U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute

